Holmusk and Veradigm announce new phase in partnership to advance real-world evidence in behavioral health

Veradigm’s $30M second phase of strategic investment to Holmusk plus provision of real-world data from millions of people treated for behavioral health is set to fuel research, innovation and care.

Veradigm, healthcare real-world data (RWD) technology company, and Holmusk a global behavioral health real-world evidence (RWE) company, have jointly announced the next stage in their strategic collaboration. Veradigm will provide RWD from millions of people treated for behavioral health and $30M investment to Holmusk, to drive research, real-world insights, and improved outcomes in behavioral health.  

Veradigm will add de-identified real-world clinical data from cohorts of millions of individuals treated for behavioral health to Holmusk’s flagship NeuroBlu Database of behavioral health RWD. This huge boost in data will be used to power deeper analyses and insights into behavioral health conditions, symptoms, and treatments – it will enable research related to challenging behavioral health questions that require targeted research cohorts.  

Holmusk will also receive $30M investment from Veradigm as part of this new phase in their collaboration. This builds upon Veradigm’s role as lead investor in Holmusk’s financing round at the start of 2023.  

Speaking exclusively to The Evidence Base, Holmusk CEO Nawal Roy commented, “Veradigm’s expanded investment marks an exciting time for Holmusk as we move forward in setting the gold standard in behavioral health data. It is clear the current care model is broken – it is missing the evidence needed to drive a transformation. By helping expand our NeuroBlu platform, the strategic partnership with Veradigm gives us the opportunity to bridge this evidence gap. With better data, we can provide more effective care, enhance research, and make mental health parity a reality.” 

“We look forward to taking this next step in our collaboration with Holmusk,” said Rick Poulton, Veradigm CEO. “Holmusk’s expertise in preparing clinical RWD for analysis, including mapping the data to a common data model, will be invaluable in unlocking new insights from our existing resources. We also believe it will enable the creation of much-needed evidence to improve behavioral health outcomes around the world.” 

The extended collaboration draws on the strengths of each company to fuel innovation in behavioral health and create the evidence needed to move the field forward. 

---

Other Holmusk news and content here.

Other Veradigm news and content here.